Tuberculosis (TB) remains one of the most persistent global health threats, primarily due to the ability of Mycobacterium tuberculosis (Mtb) to develop drug resistance and persist in the host for extended periods. The slow and grueling treatment process, often marred by relapse, underscores the urgent need for innovative solutions. Traditional drug discovery methods, which focus on genetic mutations and stable population traits, fall short in addressing the dynamic phenotypic variations that enable Mtb to evade treatment. Researchers developed a multi-condition microfluidic chip to tackle this challenge. This platform allows for high-throughput testing and precise environmental control, revolutionizing the approach to TB treatment. By focusing on phenotypic variations, the platform provides a detailed understanding of how individual bacterial cells respond to different treatments.
“In this work, we develop a multi-condition microfluidic platform suitable for imaging two-dimensional growth of bacterial cells during transitions between separate environmental conditions. With this platform, we implement a dynamic single-cell screening for pheno-tuning compounds, which induce a phenotypic change and decrease cell-to-cell variation, aiming to undermine the entire bacterial population and make it more vulnerable to other drugs.“, the authors explained.
The microfluidic device consists of 32 pairs of microchambers, each supplied by independent reservoirs. This design facilitates simultaneous testing of multiple compounds, significantly speeding up the experimental process. The platform’s long-term imaging capabilities enable researchers to observe bacterial growth and phenotypic changes in real-time, providing valuable insights into the bacteria’s behavior under various treatments.
The microfluidic device was constructed using polydimethylsiloxane (PDMS), a biocompatible material ideal for creating the intricate features needed for cell culture. The microfluidic chip integrates time-resolved microscopy to capture the behavior of live cells over time, operating on gentle hydro-pneumatic trapping to facilitate the two-dimensional growth of bacterial cells under controlled environmental conditions. The platform comprises 32 pairs of microchambers, each connected to independent reservoirs, allowing researchers to inject different solutions into each chamber and test multiple compounds simultaneously without cross-contamination.
The study identified a lead compound, M06, which increases RecA expression and reduces cell-to-cell variation, making the bacterial population more uniformly susceptible to treatment. The µDeSCRiPTor strategy allowed the researchers to pinpoint four main hits out of fewer than a hundred tested compounds that effectively pushed clonal cells into a RecA-induced state. M06 was found to impair both cellular integrity and DNA, leading to increased oxidative stress in Mtb cells. This dual mechanism of action enhances the efficacy of existing anti-tubercular drugs. Detailed spatiotemporal data obtained from the microfluidic device allowed the researchers to understand the compound’s effects more thoroughly. The lead compound M06 not only undermines the mycobacterial cell but also enhances the potency of other anti-tubercular drugs. When combined with standard antibiotics, M06 significantly reduced the survival of Mtb, demonstrating a synergistic effect that holds promise for therapeutic development.
The platform’s ability to dynamically screen for pheno-tuning compounds and monitor their effects on bacterial populations in real-time is particularly crucial for tackling pathogens that are increasingly difficult to treat. This innovative approach leverages the inherent phenotypic variation of bacterial cells, turning it into a vulnerability rather than a defense mechanism. The development and application of this microfluidic platform mark a significant milestone in TB research and treatment. It exemplifies how cutting-edge microfluidic technology can be used to address some of the most pressing challenges in global health. As we move towards a future where drug-resistant infections are a growing threat, such innovative solutions will be essential in ensuring effective and sustainable treatments.
“We expect that this approach will prove useful to identify other compounds that can enhance antimicrobial therapy, helping us to fight infections that are becoming virtually incurable.“, the authors concluded.
Figures are reproduced from Mistretta, M., Cimino, M., Campagne, P. et al. Dynamic microfluidic single-cell screening identifies pheno-tuning compounds to potentiate tuberculosis therapy. Nat Commun 15, 4175 (2024). https://doi.org/10.1038/s41467-024-48269-2 under a CC BY 4.0 Attribution 4.0 International license.
Read the original article: Dynamic microfluidic single-cell screening identifies pheno-tuning compounds to potentiate tuberculosis therapy
For more insights into the world of microfluidics and its burgeoning applications in biomedical research, stay tuned to our blog and explore the limitless possibilities that this technology unfolds. If you need high quality microfluidics chip for your experiments, do not hesitate to contact us.
In droplet microfluidics, high-throughput screening is critical for analyzing large cellular or molecular libraries at…
In the ever-evolving landscape of biochemical research, protein complexes characterization plays an important role in…
Understanding of a protein’s true behavior in biological systems remains a cornerstone for understanding biological…
Pancreatic cancer, notorious for its poor prognosis and rapid progression, remains a significant challenge in…
Understanding how microglia, the brain's immune cells, respond to inflammation is pivotal for grasping the…
Recent advancements in microfabrication of microfluidic chips are pushing the boundaries of nanoparticle design, offering…